tiprankstipranks
Trending News
More News >
Ventyx Biosciences (VTYX)
NASDAQ:VTYX
US Market

Ventyx Biosciences (VTYX) Stock Forecast & Price Target

Compare
602 Followers
See the Price Targets and Ratings of:

VTYX Analyst Ratings

Moderate Buy
8Ratings
Moderate Buy
5 Buy
3 Hold
0 Sell
Based on 8 analysts giving stock ratings to
Ventyx
Biosciences
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

VTYX Stock 12 Month Forecast

Average Price Target

$11.40
▲(448.08%Upside)
Based on 8 Wall Street analysts offering 12 month price targets for Ventyx Biosciences in the last 3 months. The average price target is $11.40 with a high forecast of $21.00 and a low forecast of $2.00. The average price target represents a 448.08% change from the last price of $2.08.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","11":"$11","22":"$22","5.5":"$5.5","16.5":"$16.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":21,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$21.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11.4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$11.40</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$2.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,5.5,11,16.5,22],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2024","6":"Oct<br/>2024","9":"Feb<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.04,3.4984615384615383,4.956923076923077,6.415384615384616,7.873846153846154,9.332307692307692,10.790769230769232,12.24923076923077,13.707692307692309,15.166153846153847,16.624615384615385,18.083076923076923,19.54153846153846,{"y":21,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.04,2.76,3.48,4.2,4.92,5.64,6.36,7.08,7.8,8.52,9.239999999999998,9.96,10.68,{"y":11.4,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.04,2.036923076923077,2.033846153846154,2.0307692307692307,2.0276923076923077,2.0246153846153847,2.0215384615384617,2.0184615384615383,2.0153846153846153,2.0123076923076924,2.0092307692307694,2.006153846153846,2.003076923076923,{"y":2,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.59,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.68,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.78,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.26,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.24,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.23,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.08,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.15,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.19,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.01,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.58,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.38,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.04,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$21.00Average Price Target$11.40Lowest Price Target$2.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Stifel Nicolaus Analyst forecast on VTYX
Unknown AnalystStifel Nicolaus
Not Ranked
Stifel Nicolaus
$2.16$2
Hold
-3.85%
Downside
Reiterated
06/23/25
Ventyx Biosciences (VTYX) Gets a Hold from Stifel Nicolaus
Canaccord Genuity Analyst forecast on VTYX
Edward NashCanaccord Genuity
Canaccord Genuity
$14
Buy
573.08%
Upside
Reiterated
06/20/25
Analysts Are Bullish on Top Healthcare Stocks: Eli Lilly & Co (LLY), Ventyx Biosciences (VTYX)
Wells Fargo Analyst forecast on VTYX
Derek ArchilaWells Fargo
Wells Fargo
$11
Buy
428.85%
Upside
Reiterated
06/18/25
Positive Outlook on Ventyx Biosciences Due to Promising Developments in Neuro-Inflammatory Treatments
Oppenheimer Analyst forecast on VTYX
Unknown AnalystOppenheimer
Not Ranked
Oppenheimer
$9
Buy
332.69%
Upside
Reiterated
06/18/25
Oppenheimer Reaffirms Their Buy Rating on Ventyx Biosciences (VTYX)
Morgan Stanley Analyst forecast on VTYX
Vikram PurohitMorgan Stanley
Morgan Stanley
Hold
Reiterated
06/17/25
Hold Rating for Ventyx Biosciences Amid Promising Early Data and Strategic Uncertainties
LifeSci Capital Analyst forecast on VTYX
Sam SlutskyLifeSci Capital
LifeSci Capital
Buy
Reiterated
06/17/25
Positive Buy Rating for Ventyx Biosciences Driven by Promising Phase 2a Trial Results and Strong Financial Position
H.C. Wainwright Analyst forecast on VTYX
Emily BodnarH.C. Wainwright
H.C. Wainwright
Hold
Reiterated
06/17/25
H.C. Wainwright Sticks to Their Hold Rating for Ventyx Biosciences (VTYX)
Piper Sandler Analyst forecast on VTYX
Yasmeen RahimiPiper Sandler
Piper Sandler
$21
Buy
909.62%
Upside
Reiterated
06/16/25
Piper Sandler Remains a Buy on Ventyx Biosciences (VTYX)
Jefferies Analyst forecast on VTYX
Michael YeeJefferies
Jefferies
$15
Buy
621.15%
Upside
Reiterated
09/23/24
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Stifel Nicolaus Analyst forecast on VTYX
Unknown AnalystStifel Nicolaus
Not Ranked
Stifel Nicolaus
$2.16$2
Hold
-3.85%
Downside
Reiterated
06/23/25
Ventyx Biosciences (VTYX) Gets a Hold from Stifel Nicolaus
Canaccord Genuity Analyst forecast on VTYX
Edward NashCanaccord Genuity
Canaccord Genuity
$14
Buy
573.08%
Upside
Reiterated
06/20/25
Analysts Are Bullish on Top Healthcare Stocks: Eli Lilly & Co (LLY), Ventyx Biosciences (VTYX)
Wells Fargo Analyst forecast on VTYX
Derek ArchilaWells Fargo
Wells Fargo
$11
Buy
428.85%
Upside
Reiterated
06/18/25
Positive Outlook on Ventyx Biosciences Due to Promising Developments in Neuro-Inflammatory Treatments
Oppenheimer Analyst forecast on VTYX
Unknown AnalystOppenheimer
Not Ranked
Oppenheimer
$9
Buy
332.69%
Upside
Reiterated
06/18/25
Oppenheimer Reaffirms Their Buy Rating on Ventyx Biosciences (VTYX)
Morgan Stanley Analyst forecast on VTYX
Vikram PurohitMorgan Stanley
Morgan Stanley
Hold
Reiterated
06/17/25
Hold Rating for Ventyx Biosciences Amid Promising Early Data and Strategic Uncertainties
LifeSci Capital Analyst forecast on VTYX
Sam SlutskyLifeSci Capital
LifeSci Capital
Buy
Reiterated
06/17/25
Positive Buy Rating for Ventyx Biosciences Driven by Promising Phase 2a Trial Results and Strong Financial Position
H.C. Wainwright Analyst forecast on VTYX
Emily BodnarH.C. Wainwright
H.C. Wainwright
Hold
Reiterated
06/17/25
H.C. Wainwright Sticks to Their Hold Rating for Ventyx Biosciences (VTYX)
Piper Sandler Analyst forecast on VTYX
Yasmeen RahimiPiper Sandler
Piper Sandler
$21
Buy
909.62%
Upside
Reiterated
06/16/25
Piper Sandler Remains a Buy on Ventyx Biosciences (VTYX)
Jefferies Analyst forecast on VTYX
Michael YeeJefferies
Jefferies
$15
Buy
621.15%
Upside
Reiterated
09/23/24
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Ventyx Biosciences

1 Month
xxx
Success Rate
8/24 ratings generated profit
33%
Average Return
-6.80%
reiterated a xxx
rating 22 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 33.33% of your transactions generating a profit, with an average return of -6.80% per trade.
3 Months
xxx
Success Rate
8/24 ratings generated profit
33%
Average Return
-15.38%
reiterated a xxx
rating 22 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 33.33% of your transactions generating a profit, with an average return of -15.38% per trade.
1 Year
Yasmeen RahimiPiper Sandler
Success Rate
8/24 ratings generated profit
33%
Average Return
-11.83%
reiterated a buy rating 22 days ago
Copying Yasmeen Rahimi's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -11.83% per trade.
2 Years
xxx
Success Rate
3/24 ratings generated profit
13%
Average Return
-55.62%
reiterated a xxx
rating 21 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 12.50% of your transactions generating a profit, with an average return of -55.62% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

VTYX Analyst Recommendation Trends

Rating
Jan 25
Feb 25
Mar 25
May 25
Jun 25
Strong Buy
2
4
3
4
7
Buy
1
2
1
3
3
Hold
4
4
2
3
5
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
7
10
6
10
15
In the current month, VTYX has received 10 Buy Ratings, 5 Hold Ratings, and 0 Sell Ratings. VTYX average Analyst price target in the past 3 months is 11.40.
Each month's total comprises the sum of three months' worth of ratings.

VTYX Financial Forecast

VTYX Earnings Forecast

Next quarter’s earnings estimate for VTYX is -$0.47 with a range of -$0.57 to -$0.39. The previous quarter’s EPS was -$0.39. VTYX beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.11% of the time in the same period. In the last calendar year VTYX has Outperformed its overall industry.
Next quarter’s earnings estimate for VTYX is -$0.47 with a range of -$0.57 to -$0.39. The previous quarter’s EPS was -$0.39. VTYX beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.11% of the time in the same period. In the last calendar year VTYX has Outperformed its overall industry.
No data currently available

VTYX Sales Forecast

Next quarter’s sales forecast for VTYX is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. VTYX beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.49% of the time in the same period. In the last calendar year VTYX has Preformed in-line its overall industry.
Next quarter’s sales forecast for VTYX is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. VTYX beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.49% of the time in the same period. In the last calendar year VTYX has Preformed in-line its overall industry.

VTYX Stock Forecast FAQ

What is VTYX’s average 12-month price target, according to analysts?
Based on analyst ratings, Ventyx Biosciences’s 12-month average price target is 11.40.
    What is VTYX’s upside potential, based on the analysts’ average price target?
    Ventyx Biosciences has 448.08% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is VTYX a Buy, Sell or Hold?
          Ventyx Biosciences has a consensus rating of Moderate Buy which is based on 5 buy ratings, 3 hold ratings and 0 sell ratings.
            What is Ventyx Biosciences’s price target?
            The average price target for Ventyx Biosciences is 11.40. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $21.00 ,the lowest forecast is $2.00. The average price target represents 448.08% Increase from the current price of $2.08.
              What do analysts say about Ventyx Biosciences?
              Ventyx Biosciences’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 8 Wall Streets Analysts.
                How can I buy shares of VTYX?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis